Omalizumab has demonstrated therapeutic benefits in controlled clinical trials. Evaluation of
outcomes in real-world clinical practice is needed to provide a complete understanding of …

Abstract We reviewed 24 'real‐life'effectiveness studies of omalizumab in the treatment of
severe allergic asthma that included 4117 unique patients from 32 countries with significant …

Omalizumab has been shown to be an effective add-on therapy for patients with
uncontrolled severe persistent allergic asthma. There has been a steady accumulation of …

Background Omalizumab is a non-steroidal medication indicated for the treatment of poorly
controlled moderate-to-severe allergic asthmatics. This observational study examines the …

Background After the approval of omalizumab for severe allergic asthma, a total of 25
studies have evaluated the effectiveness of omalizumab under “real-life” conditions of …

Currently, limited information is available to clinicians regarding the long-term efficacy of
omalizumab treatment for allergic asthma. In this report, we aimed to (i) systematically …

The ability of omalizumab, an anti-immnoglobulin‐E agent, to maintain long‐term disease
control in patients with moderate-to-severe allergic asthma was investigated in a 24‐week …

Omalizumab (Xolair®) is a subcutaneously administered monoclonal antibody that targets
circulating free IgE and prevents its interaction with the high-affinity IgE receptor (FCεRI) …

BACKGROUND: Previous reports show that addition of omalizumab to standard therapy
reduces asthma exacerbations and simultaneously decreases use of inhaled corticosteroids …

Abstract Background Randomized Controlled Trials showed that omalizumab exhibited a
good safety and tolerability profile in patients with moderate-to-severe asthma. However …